Thromboprophylaxis in Patients With Cancer and COVID-19

Interest in thromboprophylaxis has increased since the onset of the SARS-CoV-2 pandemic. It quickly became clear that patients hospitalized for COVID-19 should receive pharmacological thromboprophylaxis with low-molecular-weight heparin (LMWH), unless contraindicated (in line with long-established clinical practice guidelines on antithrombotic prophylaxis in patients hospitalized for an acute medical process).

However, early reports of a high rate of thrombotic events in some cohorts of patients hospitalized for COVID-19 despite the use of standard prophylactic doses of LMWH prompted various scientific societies and expert groups to propose the use of higher doses of LMWH in some patient subgroups.1, 2

At the time, the evidence supporting these recommendations was scant, and, as might be expected, more intense thromboprophylaxis was associated with an increase in hemorrhagic complications.3

CITA DEL ARTÍCULO  Arch Bronconeumol. 2022 Nov;58(11):744-745. doi: 10.1016/j.arbres.2022.08.006. Epub 2022 Sep 8.